Related Experiment Video
Updated: Jan 6, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Sodium channel mutations and susceptibility to heart failure and atrial fibrillation
Timothy M Olson1, Virginia V Michels, Jeffrey D Ballew
1Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA. olson.timothy@mayo.edu
Insights
Genetic defects in SCN5A are linked to dilated cardiomyopathy (DCM) and atrial fibrillation. These mutations can cause early-onset heart failure and rhythm disturbances in families.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
Background:
- Dilated cardiomyopathy (DCM) is a complex genetic heart disorder.
- While many DCM genes affect structural proteins, novel mechanisms involving ion channels are emerging.
- The complete genetic landscape of DCM remains incompletely understood.
Purpose of the Study:
- Identify a new DCM gene at a known locus.
- Characterize SCN5A mutations in a DCM patient cohort.
- Assess DCM prevalence in mutation-carrying relatives.
Main Methods:
- Fine-mapped a DCM locus on chromosome 3p in a family.
- Screened 156 DCM probands for mutations in candidate genes.
- Evaluated relatives with echocardiography, ECG, and DNA analysis.
Main Results:
- SCN5A, encoding the cardiac sodium channel, was identified as a candidate gene.
- Several SCN5A mutations (missense and truncation) were found, segregating with DCM, atrial fibrillation, and conduction defects.
- Individuals with SCN5A mutations showed variable expressivity, including early-onset DCM and atrial fibrillation.
Conclusions:
- Heritable SCN5A mutations predispose individuals to early-onset DCM and atrial fibrillation.
- SCN5A defects can manifest as heart failure, arrhythmia, or both.
- This highlights the role of sodium channel dysfunction in DCM pathogenesis.
Context:
Dilated cardiomyopathy (DCM), a genetically heterogeneous disorder, causes heart failure and rhythm disturbances. The majority of identified DCM genes encode structural proteins of the contractile apparatus and cytoskeleton. Recently, genetic defects in calcium and potassium regulation have been discovered in patients with DCM, implicating an alternative disease mechanism. The full spectrum of genetic defects in DCM, however, has not been established.
Objectives:
To identify a novel gene for DCM at a previously mapped locus, define the spectrum of mutations in this gene within a DCM cohort, and determine the frequency of DCM among relatives inheriting a mutation in this gene.
Design, Setting, And Participants:
Refined mapping of a DCM locus on chromosome 3p in a multigenerational family and mutation scanning in 156 unrelated probands with DCM, prospectively identified at the Mayo Clinic between 1987 and 2004. Relatives underwent screening echocardiography and electrocardiography and DNA sample procurement.
Main Outcome Measure:
Correlation of identified mutations with cardiac phenotype.
Results:
Refined locus mapping revealed SCN5A, encoding the cardiac sodium channel, as a candidate gene. Mutation scans identified a missense mutation (D1275N) that cosegregated with an age-dependent, variably expressed phenotype of DCM, atrial fibrillation, impaired automaticity, and conduction delay. In the DCM cohort, additional missense (T220I, R814W, D1595H) and truncation (2550-2551insTG) SCN5A mutations, segregating with cardiac disease or arising de novo, were discovered in unrelated probands. Among individuals with an SCN5A mutation 27% had early features of DCM (mean age at diagnosis, 20.3 years), 38% had DCM (mean age at diagnosis, 47.9 years), and 43% had atrial fibrillation (mean age at diagnosis, 27.8 years).
Conclusions:
Heritable SCN5A defects are associated with susceptibility to early-onset DCM and atrial fibrillation. Similar or even identical mutations may lead to heart failure, arrhythmia, or both.
Related Concept Videos
Heart Failure II: Pathophysiology
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Diuretics

